C07D 277/00
Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
C07D277/00 (Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings) appears on 8,659 US grants and 7,219 published applications in this corpus.
Search patents in C07D- Granted patents
- 8,659
- Published applications
- 7,219
- Assignees
- 2,663
- Inventors
- 21,070
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 95 | 0 |
| 1977 | 130 | 0 |
| 1978 | 118 | 0 |
| 1979 | 79 | 0 |
| 1980 | 115 | 0 |
| 1981 | 142 | 0 |
| 1982 | 103 | 0 |
| 1983 | 130 | 0 |
| 1984 | 153 | 0 |
| 1985 | 116 | 0 |
| 1986 | 109 | 0 |
| 1987 | 116 | 0 |
| 1988 | 123 | 0 |
| 1989 | 133 | 0 |
| 1990 | 147 | 0 |
| 1991 | 148 | 0 |
| 1992 | 121 | 0 |
| 1993 | 178 | 0 |
| 1994 | 144 | 0 |
| 1995 | 161 | 0 |
| 1996 | 170 | 0 |
| 1997 | 183 | 0 |
| 1998 | 175 | 0 |
| 1999 | 167 | 0 |
| 2000 | 162 | 0 |
| 2001 | 224 | 49 |
| 2002 | 208 | 225 |
| 2003 | 201 | 363 |
| 2004 | 188 | 424 |
| 2005 | 170 | 391 |
| 2006 | 223 | 356 |
| 2007 | 220 | 332 |
| 2008 | 204 | 343 |
| 2009 | 191 | 389 |
| 2010 | 257 | 413 |
| 2011 | 234 | 316 |
| 2012 | 281 | 280 |
| 2013 | 246 | 293 |
| 2014 | 319 | 337 |
| 2015 | 279 | 305 |
| 2016 | 230 | 284 |
| 2017 | 241 | 258 |
| 2018 | 202 | 254 |
| 2019 | 209 | 221 |
| 2020 | 163 | 236 |
| 2021 | 162 | 205 |
| 2022 | 131 | 230 |
| 2023 | 111 | 242 |
| 2024 | 131 | 209 |
| 2025 | 127 | 164 |
| 2026 | 89 | 100 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- 5-membered heteroarylaminosulfonamides for treating conditions mediated by deficient CFTR activity6 Oct 2026US 12,753,171 B2Genzyme Corporation
- Compounds and methods of inhibiting bacterial chaperonin systems29 Sep 2026US 12,747,219 B2Arizona Board of Regents on Behalf of the University of Arizona
- Tautomeric ligand enables biomimetic C—H hydroxylation with molecular oxygen22 Sep 2026US 12,741,937 B2The Scripps Research Institute
- Inhibitors of spinster homolog 2 (SPNS2) for use in therapy22 Sep 2026US 12,741,944 B2University of Virginia Patent Foundation
- Benzothiazole and quinoline derivatives and their use22 Sep 2026US 12,741,948 B2Shanghai Yao Yuan Biotechnology Co., Ltd.
- Mitochondrial uncouplers for treatment of metabolic diseases and cancer8 Oct 2026US 2026/0306502 A1Mito Biopharma, LLC
- Probenecid compounds for the treatment of inflammasome-mediated lung disease8 Oct 2026US 2026/0308131 A1Bacainn Biotherapeutics, Ltd.
- Therapeutic compounds1 Oct 2026US 2026/0297016 A1Regents of the University of Minnesota
- Biarylamide derivatives and their use as pkmyt1 inhibitors1 Oct 2026US 2026/0297042 A1Cancer Research Technology Limited
- Hdac1/2 selective inhibitor and use thereof1 Oct 2026US 2026/0297110 A1Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Most cited
By later US patents
- Phenyl heterocycles as cox-2 inhibitors281US 5,474,995 AMerck Frosst Canada, Inc. · 1995
- Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof277US 5,549,974 AAffymax Technologies N.V. · 1996
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase226US 5,480,883 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1996
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase209US 5,409,930 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1995
- Phenyl heterocycles as cox-2 inhibitors208US 5,550,142 AMerck Frosst Canada, Inc. · 1996